Page 2008 - Hematology_ Basic Principles and Practice ( PDFDrive )

1780.e2 Part XI Transfusion Medicine

of unknown etiology. Biochem Biophys Res Commun 241(1):92–97, 72. Mannucci PM, Carlsson S, Harris AS: Desmopressin, surgery and
1997. thrombosis. Thromb Haemost 71(1):154–155, 1994.
49. Advisory NHFM, editor: Ongoing recombinant factor VIII shortage 73. Parti R, Schoppmann A, Lee H, et al: Stability of lyophilized and
contingency recommendations, 2000, p 371. reconstituted plasma/albumin-free recombinant human factor VIII
50. Larsson SA: Life expectancy of Swedish haemophiliacs, 1831-1980. Br (ADVATE rAHF-PFM). Haemophilia 11(5):492–496, 2005.
J Haematol 59(4):593–602, 1985. 74. Osterberg T, Fatouros A, Neidhardt E, et al: B-domain deleted recom-
51. Ragni MV, Tegtmeier GE, Levy JA, et al: AIDS retrovirus antibodies binant factor VIII formulation and stability. Semin Hematol 38(2 Suppl
in hemophiliacs treated with factor VIII or factor IX concentrates, 4):40–43, 2001.
cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, 75. Abshire TC, Brackmann HH, Scharrer I, et al: Sucrose formulated
and clinical correlations. Blood 67(3):592–595, 1986. recombinant human antihemophilic factor VIII is safe and effica-
52. Ragni MV, Winkelstein A, Kingsley L, et al: 1986 update of HIV cious for treatment of hemophilia A in home therapy–International
seroprevalence, seroconversion, AIDS incidence, and immunologic Kogenate-FS Study Group. Thromb Haemost 83(6):811–816, 2000.
correlates of HIV infection in patients with hemophilia A and B. Blood 76. Eloctate. Biogen idec; 2014.
70(3):786–790, 1987. 77. Shima M, Hanabusa H, Taki M, et al: Safety and prophylactic efficacy
53. Clearinghouse WI, editor: Hemophilia Statistics: 1998 survey, 1998. profiles of ACE910, a humanized bispecific antibody mimicking the
54. Gjerset GF, Clements MJ, Counts RB, et al: Treatment type and FVIII cofactor function, in Japanese hemophilia A patients both
amount influenced human immunodeficiency virus seroprevalence of without and with FVIII inhibitors: first-in-patient phase 1 study. Blood
patients with congenital bleeding disorders. Blood 78(6):1623–1627, 124:691, 2014.
1991. 78. Nathwani AC, Tuddenham EG, Rangarajan S, et al: Adenovirus-
55. Burnouf T, Radosevich M: Nanofiltration of plasma-derived biophar- associated virus vector-mediated gene transfer in hemophilia B. N Engl
maceutical products. Haemophilia 9(1):24–37, 2003. J Med 365(25):2357–2365, 2011.
56. Teitel JM: Safety of coagulation factor concentrates. Haemophilia 79. Nathwani AC, Reiss UM, Tuddenham EG, et al: Long-term safety
4(4):393–401, 1998. and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med
57. Ljung RC: Can haemophilic arthropathy be prevented? Br J Haematol 371(21):1994–2004, 2014.
101(2):215–219, 1998. 80. Cheung WF, van den Born J, Kuhn K, et al: Identification of the
58. Foundation NH: Medical and Scientific Advisory Council (MASAC) endothelial cell binding site for factor IX. Proc Natl Acad Sci USA
Recommendation Concerning Prophylaxis: Regular Administration 93(20):11068–11073, 1996.
of Clotting Factor Concentrate to Prevent Bleeding (179). <http:// 81. White GC, 2nd, Beebe A, Nielsen B: Recombinant factor IX. Thromb
www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57 Haemost 78(1):261–265, 1997.
&contentid=1007>. 82. Blatt PM, Lundblad RL, Kingdon HS, et al: Thrombogenic materials
59. Lillicrap D: New Advances in the Treatment of Children with Hemo- in prothrombin complex concentrates. Ann Intern Med 81(6):766–770,
philia. In Branski DKW, editor: Pediatric and Adolescent Medicine (vol 1974.
17). Pediatr Adolesc Med. Basel, 2014, Karger, pp 67–80. 83. Roberts HBM: Other coagulation factor deficiencies, 1999, Blackwell
60. Ragni MV, Fogarty PJ, Josephson NC, et al: Survey of current pro- Scientific.
phylaxis practices and bleeding characteristics of children with severe 84. BeneFIX Prescribing Information. <https://www.pfizerpro.com/product/
haemophilia A in US haemophilia treatment centres. Haemophilia benefix/hemophilia-b>.
2011. 85. Warrier I: Management of haemophilia B patients with inhibitors and
61. Feldman BM, Pai M, Rivard GE, et al: Tailored prophylaxis in severe anaphylaxis. Haemophilia 4(4):574–576, 1998.
hemophilia A: interim results from the first 5 years of the Canadian 86. Alprolix. Biogen idec; 2014.
Hemophilia Primary Prophylaxis Study. J Thromb Haemost 4(6):1228– 87. Ehrenforth S, Kreuz W, Scharrer I, et al: Incidence of development
1236, 2006. of factor VIII and factor IX inhibitors in haemophiliacs. Lancet
62. Ragni M, Fogarty P, Josephson N, et al: The Hempohilia Inihibit Study: 339(8793):594–598, 1992.
A prospective randomized trial of rFVIII to prevent inhibitor formation 88. Scharrer I, Bray GL, Neutzling O: Incidence of inhibitors in hae-
in children with hemophilia (abstract). Paper presented at: Hemophilia mophilia A patients–a review of recent studies of recombinant and
Thrombosis Research Society of North America; April 16-18, 2010; plasma-derived factor VIII concentrates. Haemophilia 5(3):145–154,
Chicago, IL. 1999.
63. DiMichele D: Hemophilia 1996. New approach to an old disease. 89. High KA, Factor IX: molecular structure, epitopes, and mutations
Pediatr Clin North Am 43(3):709–736, 1996. associated with inhibitor formation. Adv Exp Med Biol 386:79–86,
64. Mannucci PM: Haemophilia treatment protocols around the world: 1995.
towards a consensus. Haemophilia 4(4):421, 1998. 90. Warrier I, Ewenstein BM, Koerper MA, et al: Factor IX inhibitors and
65. Lusher J: Treatment of congenital coagulopathies, Bethesda, MD, 1999, anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 19(1):23–27,
AABB Press. 1997.
66. Santagostino E, Gringeri A, Berardinelli L, et al: Long-term safety and 91. Warrier I, Lusher JM: Development of anaphylactic shock in haemo-
feasibility of arteriovenous fistulae as vascular accesses in children with philia B patients with inhibitors. Blood Coagul Fibrinolysis 9(Suppl
haemophilia: a prospective study. Br J Haematol 123(3):502–506, 2003. 1):S125–S128, 1998.
67. Valentino LA, Ewenstein B, Navickis RJ, et al: Central venous access 92. Faranoush M, Abolghasemi H, Mahboudi F, et al: A comparison of
devices in haemophilia. Haemophilia 10(2):134–146, 2004. efficacy between recombinant activated factor VII (Aryoseven) and
68. Price VE, Carcao M, Connolly B, et al: A prospective, longitudinal Novoseven in patients with hereditary FVIII deficiency with inhibitor.
study of central venous catheter-related deep venous thrombosis in boys Clin Appl Thromb Hemost 2014.
with hemophilia. J Thromb Haemost 2(5):737–742, 2004. 93. Green D: Complications associated with the treatment of haemophiliacs
69. Mancuso ME, Berardinelli L, Beretta C, et al: Improved treatment with inhibitors. Haemophilia 5(Suppl 3):11–17, 1999.
feasibility in children with hemophilia using arteriovenous fistulae: the 94. Aledort LM: rFVIIa–its thrombogenicity. Thromb Haemost 84(3):522–
results after seven years of follow-up. Haematologica 94(5):687–692, 523, 2000.
2009. 95. Kohler M: Thrombogenicity of prothrombin complex concentrates.
70. Journeycake JM, Quinn CT, Miller KL, et al: Catheter-related deep Thromb Res 95(4 Suppl 1):S13–S17, 1999.
venous thrombosis in children with hemophilia. Blood 98(6):1727– 96. DiMichele DM: Inhibitors in haemophilia: a primer. Haemophilia
1731, 2001. 6(Suppl 1):38–40, 2000.
71. Revel-Vilk S, Blanchette VS, Sparling C, et al: DDAVP challenge 97. Leissinger C, Gringeri A, Antmen B, et al: Anti-Inhibitor Coagulant
tests in boys with mild/moderate haemophilia A. Br J Haematol Complex Prophylaxis in Hemophilia with Inhibitors. N Engl J Med
117(4):947–951, 2002. 365(18):1684–1692, 2011.